Eyes on the Lid: The Impact of Fibroblast Growth Factor Receptor Targeting Drug on Human Meibomian Gland.

IF 2 4区医学 Q2 OPHTHALMOLOGY

Eye & Contact Lens-Science and Clinical Practice Pub Date : 2024-02-01 Epub Date: 2023-11-21 DOI:10.1097/ICL.0000000000001058

Xiaomin Chen, Yang Liu, Tian Zheng, Qiuyan Zhang, Yaoyao Ren, Yanru Shen, Min Ke

{"title":"Eyes on the Lid: The Impact of Fibroblast Growth Factor Receptor Targeting Drug on Human Meibomian Gland.","authors":"Xiaomin Chen, Yang Liu, Tian Zheng, Qiuyan Zhang, Yaoyao Ren, Yanru Shen, Min Ke","doi":"10.1097/ICL.0000000000001058","DOIUrl":null,"url":null,"abstract":"Objective: To determine whether fibroblast growth factor receptor (FGFR)-targeting drug could impact human meibomian gland.Methods: We followed up with three patients who were using pemigatinib for 4 to 10 weeks. The patients were evaluated for their ocular surface disease index, best-corrected visual acuity, Schirmer test, cornea staining, meibum expressibility score, tear meniscus height, noninvasive tear film breakup time, and meibomian gland area. The distribution of the FGFR family, FGF7, and FGF10 were evaluated by immunofluorescence staining and Western blot in fresh tarsal tissues from deidentified patients who underwent lid plastic surgeries.Results: All patients developed apparent meibomian gland atrophy, shortening and narrowing of ducts, and significantly increased meibum expressibility and decreased noninvasive tear film breakup time within 5 to 8 weeks. Laboratory evaluations confirmed that human meibomian gland expresses abundant fibroblast growth factor receptors.Conclusions: These findings indicate that meibomian gland is a target tissue of FGFR inhibitors, and patients who use these drugs may develop meibomian gland dysfunction.","PeriodicalId":50457,"journal":{"name":"Eye & Contact Lens-Science and Clinical Practice","volume":" ","pages":"102-105"},"PeriodicalIF":2.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye & Contact Lens-Science and Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICL.0000000000001058","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To determine whether fibroblast growth factor receptor (FGFR)-targeting drug could impact human meibomian gland.

Methods: We followed up with three patients who were using pemigatinib for 4 to 10 weeks. The patients were evaluated for their ocular surface disease index, best-corrected visual acuity, Schirmer test, cornea staining, meibum expressibility score, tear meniscus height, noninvasive tear film breakup time, and meibomian gland area. The distribution of the FGFR family, FGF7, and FGF10 were evaluated by immunofluorescence staining and Western blot in fresh tarsal tissues from deidentified patients who underwent lid plastic surgeries.

Results: All patients developed apparent meibomian gland atrophy, shortening and narrowing of ducts, and significantly increased meibum expressibility and decreased noninvasive tear film breakup time within 5 to 8 weeks. Laboratory evaluations confirmed that human meibomian gland expresses abundant fibroblast growth factor receptors.

Conclusions: These findings indicate that meibomian gland is a target tissue of FGFR inhibitors, and patients who use these drugs may develop meibomian gland dysfunction.

查看原文本刊更多论文

眼睑上的眼睛:成纤维细胞生长因子受体靶向药物对人睑板腺的影响。

目的:探讨以成纤维细胞生长因子受体(FGFR)为靶点的药物对人睑板腺的影响。方法:对3例使用培伽替尼的患者进行4 ~ 10周的随访。评估患者的眼表疾病指数、最佳矫正视力、Schirmer试验、角膜染色、睑板表达性评分、撕裂半月板高度、无创撕裂膜破裂时间、睑板腺面积。通过免疫荧光染色和Western blot方法，对接受眼睑整形手术的未识别患者新鲜跗骨组织中FGFR家族、FGF7和FGF10的分布进行了评估。结果:所有患者在5 ~ 8周内均出现睑板腺明显萎缩，导管变短变窄，睑板表达能力明显提高，无创撕裂膜破裂时间明显缩短。实验室评估证实，人睑板腺表达丰富的成纤维细胞生长因子受体。结论:这些发现提示睑板腺是FGFR抑制剂的靶组织，使用这些药物的患者可能出现睑板腺功能障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Eye & Contact Lens-Science and Clinical Practice OPHTHALMOLOGY-

CiteScore

4.50

自引率

4.30%

发文量

150

审稿时长

6-12 weeks

期刊介绍： Eye & Contact Lens: Science and Clinical Practice is the official journal of the Contact Lens Association of Ophthalmologists (CLAO), an international educational association for anterior segment research and clinical practice of interest to ophthalmologists, optometrists, and other vision care providers and researchers. Focusing especially on contact lenses, it also covers dry eye disease, MGD, infections, toxicity of drops and contact lens care solutions, topography, cornea surgery and post-operative care, optics, refractive surgery and corneal stability (eg, UV cross-linking). Peer-reviewed and published six times annually, it is a highly respected scientific journal in its field.